CoChat
Sign Up
Cited by 38Epilepsy research and treatmentTraumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury Research

Targeting neurodegeneration to prevent post-traumatic epilepsy.

Open access
Ali, Idrish, Silva, Juliana C., Liu, Shijie, Shultz, Sandy R., Kwan, Patrick, Jones, Nigel C., O'Brien, Terence J.·2019·Neurobiology of Disease
DOI 10.1016/j.nbd.2018.08.006PMC PMC6348126
Open this paper in CoChat — free account

Abstract

In the quest for developing new therapeutic targets for post-traumatic epilepsies (PTE), identifying mechanisms relevant to development and progression of disease is critical. A growing body of literature suggests involvement of neurodegenerative mechanisms in the pathophysiology of acquired epilepsies, including following traumatic brain injury (TBI). In this review, we discuss the potential of some of these mechanisms to be targets for the development of a therapy against PTE.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2018.08.006

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neurodegenerative conditions characterized by hyperphosphorylated tau aggregations exhibit increased rates of epilepsy.

    “Given that neurodegenerative conditions characterized by hyperphosphorylated tau aggregations exhibit increased rates of epilepsy, epilepsies are being re-conceptualized within a tauopathy context (Xi et al., 2011; Sanchez et al., 2018; Ali et al., 2019).”

    From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Ali et al., 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 138

  1. Aboud O,, 2013 Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. Acta Neuropathol. Commun 1, 41. 24252240 PMC3893449
  2. Abou-Khalil BW, 2010 How important is Alzheimer’s disease as a risk factor for unprovoked seizures and epilepsy in the elderly? Epilepsy Curr 10 (2), 36– 37. 20231919 PMC2836473
  3. Acharya MM,, 2008 Progress in neuroprotective strategies for preventing epilepsy. Prog. Neurobiol 84, 363– 404. 18207302 PMC2441599
  4. Agadi S, Shetty AK, 2015 Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy. Stem Cells 33, 2093– 2103. 25851047 PMC7023904
  5. Albayram O,, 2017 Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nat. Commun 8. PMC5645414 29042562
  6. Ali I,, 2017a Intracerebral delivery of the M2 polarizing cytokine interleukin 13 using mesenchymal stem cell implants in a model of temporal lobe epilepsy in mice. Epilepsia 58, 1063– 1072. 28374921
  7. Ali I,, 2018 Decreased post-synaptic density-95 protein expression on dendrites of newborn neurons following CX3CR1 modulation in the epileptogenic adult rodent brain. Cell Mol. Immunol 15 (4), 414– 417. 29082919 PMC6052830
  8. Amatniek JC,, 2006 Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47, 867– 872. 16686651
  9. Amhaoul H,, 2016 P2X7 receptor antagonism inhibits seizure severity in a chronic model of temporal lobe epilepsy. Neuropharmacology 105, 175– 185. 26775823
  10. An SJ,, 2003 Accumulation of microtubule-associated proteins in the hippocampal neurons of seizure-sensitive gerbils. Mol. Cells 15, 200– 207. 12803483
  11. Aronica E,, 2017 Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia 58 (Suppl. 3), 27– 38. PMC5873599 28675563
  12. Avoli M,, 2016 Specific imbalance of excitatory/inhibitory signaling establishes seizure onset pattern in temporal lobe epilepsy. J. Neurophysiol 115, 3229– 3237. 27075542 PMC4946603
  13. Bakker A,, 2015 Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin 7, 688– 698. 25844322 PMC4377841
  14. Benson MJ,, 2015 Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models. Epilepsia 56, 895– 905. 25847097
  15. Bertoglio D,, 2017 Kainic acid-induced post-status epilepticus models of temporal lobe epilepsy with diverging seizure phenotype and neuropathology. Front. Neurol 8, 588. 29163349 PMC5681498
  16. Bhowmik M,, 2015 Activation of AKT/GSK3beta pathway by TDZD-8 attenuates kainic acid induced neurodegeneration but not seizures in mice. Neurotoxicology 46, 44– 52. 25453207
  17. Blennow K,, 2012 The neuropathology and neurobiology of traumatic brain injury. Neuron 76, 886– 899. 23217738
  18. Born HA,, 2014 Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer’s disease. J. Neurosci 34, 3826– 3840. 24623762 PMC3951689
  19. Brandt C,, 2006 Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51, 789– 804. 16806297
  20. Busche MA,, 2008 Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science 321, 1686– 1689. 18802001
  21. Busche MA,, 2012 Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A 109, 8740– 8745. 22592800 PMC3365221
  22. Cabrejo L,, 2006 Phenotype associated with APP duplication in five families. Brain 129, 2966– 2976. 16959815
  23. Carletti F,, 2016 Hippocampal hyperexcitability is modulated by microtubule-active agent: evidence from in vivo and in vitro epilepsy models in the rat. Front. Cell. Neurosci 10, 29. 26903814 PMC4746529
  24. Chen LJ,, 2010 Compression alters kinase and phosphatase activity and tau and MAP2 phosphorylation transiently while inducing the fast adaptive dendritic remodeling of underlying cortical neurons. J. Neurotrauma 27, 1657– 1669. 20568963
  25. Chugh D,, 2015 Alterations in brain inflammation, synaptic proteins, and adult hippocampal neurogenesis during epileptogenesis in mice lacking synapsin2. PLoS One 10, e0132366. 26177381 PMC4503715
  26. Cirrito JR,, 2005 Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913– 922. 16364896
  27. Corcoran NM,, 2010 Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br. J. Cancer 103, 462– 468. 20648008 PMC2939789
  28. Corrigan F,, 2011 The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res 1378, 137– 143. 21215734
  29. Corrigan F,, 2012a Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury. Brain Res 1451, 87– 99. 22424792
  30. Corrigan F,, 2012b sAPPalpha rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J. Neurochem 122, 208– 220. 22519988
  31. Corrigan F,, 2014 The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96–110. J. Neurochem 128, 196– 204. 23919582
  32. Decker JM,, 2016 The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Rep 17, 552– 569. 26931569 PMC4818782
  33. Desena AD,, 2018 Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade. J. Neuroinflammation 15, 38. 29426321 PMC5807745
  34. Devos SL,, 2013 Antisense reduction of tau in adult mice protects against seizures. J. Neurosci 33, 12887– 12897. 23904623 PMC3728694
  35. Engel T,, 2006 Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem 99, 1445– 1455. 17059563
  36. Folkerts MM,, 1998 Disruption of MAP-2 immunostaining in rat hippocampus after traumatic brain injury. J. Neurotrauma 15, 349– 363. 9605349
  37. Forsgren L,, 1996 Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study. Epilepsia 37, 224– 229. 8598179
  38. Fukuda M,, 2009 Interleukin-1beta enhances susceptibility to hyperthermia-induced seizures in developing rats. Seizure 18, 211– 214. 19004647
  39. Gao J,, 2016 Human Neural Stem Cell Transplantation-Mediated Alteration of Microglial/Macrophage Phenotypes after Traumatic Brain Injury. Cell Transplant 25, 1863– 1877. 26980267
  40. Gheyara AL,, 2014 Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol 76, 443– 456. 25042160 PMC4338764
  41. Ghosal K, Pimplikar SW, 2011 Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice. Neurobiol. Aging 32, 2320 (e1– 9). PMC2928862 20493588
  42. Giorgi FS,, 2017 Treatment of epilepsy in patients with Alzheimer’s disease. Expert. Rev. Neurother 17, 309– 318. 27687685
  43. Hatch RJ,, 2017 Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol 133, 717– 730. 28091722 PMC5389999
  44. Hawkins BE,, 2013 Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury. J. Biol. Chem 288, 17042– 17050. 23632019 PMC3675635
  45. Hayashi T,, 2015 Two different immunostaining patterns of beta-amyloid precursor protein (APP) may distinguish traumatic from nontraumatic axonal injury. Int. J. Legal Med 129, 1085– 1090. 26249371
  46. Heneka MT,, 2015 Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14, 388– 405. 25792098 PMC5909703
  47. Holth JK,, 2013 Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci 33, 1651– 1659. 23345237 PMC3711605
  48. Hortobagyi T,, 2007 Traumatic axonal damage in the brain can be detected using beta-APP immunohistochemistry within 35 min after head injury to human adults. Neuropathol. Appl. Neurobiol 33, 226– 237. 17359363
  49. Huang WJ,, 2013 GSK-3beta may be involved in hippocampal mossy fiber sprouting in the pentylenetetrazole-kindling model. Mol. Med. Rep 8, 1337– 1342. 24002180
  50. Huijbers W,, 2015 Amyloid-beta deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain 138, 1023– 1035. 25678559 PMC4438387
  51. Hung SY, Fu WM, 2017 Drug candidates in clinical trials for Alzheimer’s disease. J. Biomed. Sci 24, 47. 28720101 PMC5516350
  52. Iori V,, 2016 Modulation of neuronal excitability by immune mediators in epilepsy. Curr. Opin. Pharmacol 26, 118– 123. 26629681 PMC4716878
  53. Jassam YN,, 2017 Neuroimmunology of traumatic brain injury: time for a paradigm shift. Neuron 95, 1246– 1265. 28910616 PMC5678753
  54. Jones NC,, 2012 Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol. Dis 45, 897– 901. 22182692
  55. Kandratavicius L,, 2013 Microtubule-associated proteins in mesial temporal lobe epilepsy with and without psychiatric comorbidities and their relation with granular cell layer dispersion. Biomed. Res. Int 2013, 960126. 24069608 PMC3771259
  56. Kenney K,, 2018 Dementia after moderate-severe traumatic brain injury: coexistence of multiple proteinopathies. J. Neuropathol. Exp. Neurol 77, 50– 63. 29155947 PMC5939622
  57. Kenney-Jung DL,, 2016 Febrile infection-related epilepsy syndrome treated with anakinra. Ann. Neurol 80, 939– 945. 27770579 PMC5225882
  58. Kondo A,, 2015 Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431– 436. 26176913 PMC4718588
  59. Kulbe JR, Hall ED, 2017 Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology. Prog. Neurobiol 158, 15– 44. 28851546 PMC5671903
  60. Laatsch LK,, 2004 Investigating the neurobiological basis of cognitive rehabilitation therapy with fMRI. Brain Inj 18, 957– 974. 15370896
  61. Le Feuvre R,, 2002 Extracellular ATP and P2X7 receptors in neurodegeneration. Eur. J. Pharmacol 447, 261– 269. 12151017
  62. Lee G, Leugers CJ, 2012 Tau and tauopathies. Prog. Mol. Biol. Transl. Sci 107, 263– 293. 22482453 PMC3614411
  63. Lewen A,, 1995 Traumatic brain injury in rat produces changes of beta-amyloid precursor protein immunoreactivity. Neuroreport 6, 357– 360. 7756628
  64. Lewen A,, 1996 Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: influence of MK-801 treatment. Brain Res 719, 161– 171. 8782876
  65. Li Z,, 2014 Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging 35, 2617– 2624. 24908165 PMC4171213
  66. Liou YC,, 2003 Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424, 556– 561. 12891359
  67. Liu SJ,, 2017a Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. Epilepsia 58, E136– E141. 28710841
  68. Liu X,, 2017b N-methyl-D-aspartate receptors mediate epilepsy-induced axonal impairment and tau phosphorylation via activating glycogen synthase kinase-3beta and cyclin-dependent kinase 5. Discov. Med 23, 221– 234. 28595035
  69. Loane DJ,, 2009 Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat. Med 15, 377– 379. 19287391 PMC2844765
  70. Lozano D,, 2015 Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr. Dis. Treat 11, 97– 106. PMC4295534 25657582
  71. Magnoni S, Brody DL, 2010 New perspectives on amyloid-beta dynamics after acute brain injury: moving between experimental approaches and studies in the human brain. Arch. Neurol 67, 1068– 1073. 20837849
  72. Malpas CB,, 2016 A Phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer’s disease. J. Alzheimers Dis 54, 223– 232. 27447428
  73. Masters CL, Selkoe DJ, 2012 Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med 2, a006262. 22675658 PMC3367542
  74. Matsumoto G, Sakai H, 1979 Microtubules inside the plasma membrane of squid giant axons and their possible physiological function. J. Membr. Biol 50, 1– 14. 501731
  75. McKee AC,, 2013 The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43– 64. 23208308 PMC3624697
  76. Mehan S,, 2011 JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer’s and various neurodegenerative abnormalities. J. Mol. Neurosci 43, 376– 390. 20878262
  77. Mendez M, Lim G, 2003 Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 20, 791– 803. 12964886
  78. Menendez M, 2005 Down syndrome, Alzheimer’s disease and seizures. Brain Dev 27, 246– 252. 15862185
  79. Minkeviciene R,, 2009 Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci 29, 3453– 3462. 19295151 PMC6665248
  80. Miszczuk D,, 2016 Traumatic Brain Injury Increases the Expression of Nos1, Abeta Clearance, and Epileptogenesis in APP/PS1 Mouse Model of Alzheimer’s Disease. Mol. Neurobiol 53, 7010– 7027. 26671618
  81. Mockett BG,, 2017 Therapeutic potential of secreted amyloid precursor protein APPsalpha. Front. Mol. Neurosci 10, 30. 28223920 PMC5293819
  82. Mondragon Rodriguez S,, 2018 Phosphorylation of tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer’s model. J. Biol. Chem 293 (22), 8462– 8472. 29632073 PMC5986208
  83. Monti G,, 2015 Cerebrospinal fluid tau proteins in status epilepticus. Epilepsy Behav 49, 150– 154. 25958230
  84. Mucke L, Selkoe DJ, 2012 Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med 2, a006338. 22762015 PMC3385944
  85. Nakagawa Y,, 1999 Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J. Comp. Neurol 411, 390– 398. 10413774
  86. Nakamura K,, 2012 Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease. Cell 149, 232– 244. 22464332 PMC3601591
  87. Nicastro N, Assal F, Seeck M, 2016 From here to epilepsy: the risk of seizure in patients with Alzheimer’s disease. Epileptic Disord 18 (1), 1– 12. 26907471
  88. Noble W,, 2005 Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A 102, 6990– 6995. 15867159 PMC1088065
  89. Noe FM,, 2013 Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol. Dis 59, 183– 193. 23938763
  90. Noebels J, 2011 A perfect storm: Converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation. Epilepsia 52 (Suppl. 1), 39– 46. PMC3058398 21214538
  91. Okuneva O,, 2015 Abnormal microglial activation in the Cstb(−/−) mouse, a model for progressive myoclonus epilepsy, EPM1. Glia 63, 400– 411. 25327891
  92. Olivera A,, 2015 Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol 72, 1109– 1116. 26237304
  93. Otsuka N,, 1991 Rapid appearance of beta-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury. Brain Res 568, 335– 338. 1814579
  94. Palmio J,, 2009 Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. Seizure 18, 474– 477. 19428269
  95. Palop JJ, Mucke L, 2016 Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci 17, 777– 792. 27829687 PMC8162106
  96. Palop JJ,, 2007 Aberrant excitatory neuronal activity and compensatory remodelin of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55, 697– 711. 17785178 PMC8055171
  97. Papa L,, 2018 Temporal profile of microtubule-associated protein 2: a novel indicator of diffuse brain injury severity and early mortality after brain trauma. J. Neurotrauma 35, 32– 40. 28895474 PMC5757083
  98. Pitkanen A,, 2005 Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res 63, 27– 42. 15716080
  99. Posmantur RM,, 1996 Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury. J. Neurotrauma 13, 125– 137. 8965322
  100. Rehman SU,, 2017 Inhibition of c-Jun N-terminal kinase protects against brain damage and improves learning and memory after traumatic brain injury in adult mice. Cereb. Cortex 1– 19. 29088310
  101. Ren SQ,, 2018 Amyloid beta causes excitation/inhibition imbalance through dopamine receptor 1-dependent disruption of fast-spiking GABAergic input in anterior cingulate cortex. Sci. Rep 8, 302. 29321592 PMC5762926
  102. Risse SC,, 1990 Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis. Assoc. Disord 4, 217– 225. 2264979
  103. Roberson ED,, 2007 Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316, 750– 754. 17478722
  104. Rostgaard N,, 2015 Cerebrospinal fluid biomarkers in familial forms of Alzheimer’s disease and frontotemporal dementia. Dement. Geriatr. Cogn. Disord 40, 54– 62. 25998699
  105. Saletti PG, Ali I, Casillas-Espinosa PM, Semple BD, Lisgaras C, Moshe SL, Galanopoulou AS, 2018 In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis PMC6309524 29936231
  106. Sanchez C,, 2000 Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog. Neurobiol 61, 133– 168. 10704996
  107. Sanchez-Elexpuru G,, 2017 Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease. Epilepsia 58, 467– 475. 28098937 PMC5495962
  108. Savina TA, Shchipakina TG, 2011 cAMP-dependent phosphorylation of microtubuleassociated protein-2 during treatment of sodium valproate and audiogenic kindling. Bull. Exp. Biol. Med 152, 53– 57. 22803039
  109. Scarmeas N,, 2009 Seizures in Alzheimer disease: who, when, and how common? Arch. Neurol 66, 992– 997. 19667221 PMC2768279
  110. Schenk D,, 2012 Treatment strategies targeting amyloid beta-protein. Cold Spring Harb. Perspect. Med 2, a006387. 22951439 PMC3426815
  111. Semple BD,, 2017 Interleukin-1 receptor in seizure susceptibility after traumatic injury to the pediatric brain. J. Neurosci 37, 7864– 7877. 28724747 PMC5559762
  112. Sen A,, 2007 Pathological tau tangles localize to focal cortical dysplasia in older patients. Epilepsia 48, 1447– 1454. 17441989
  113. Seo JS,, 2017 Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy. Exp. Mol. Med 49. PMC5454448 28524178
  114. Shahim P,, 2014 Cerebrospinal fluid biomarkers of beta-amyloid metabolism and neuronal damage in epileptic seizures. Eur. J. Neurol 21, 486– 491. 24372994
  115. Shoji M,, 2000 JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res. Mol. Brain Res 85, 221– 233. 11146125
  116. Shultz SR,, 2015 Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain 138, 1297– 1313. 25771151 PMC5963409
  117. Small DH,, 1994 A heparin-binding domain in the amyloid protein precursor of Alzheimer’s disease is involved in the regulation of neurite outgrowth. J. Neurosci 14, 2117– 2127. 8158260 PMC6577125
  118. Sotiropoulos I,, 2017 Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathol. Commun 5, 91. 29187252 PMC5707803
  119. Sun JJ,, 2015 Echinoderm microtubule-associated protein -like protein 5 in anterior temporal neocortex of patients with intractable epilepsy. Iran J. Basic Med. Sci 18, 1008– 1013. 26730336 PMC4686571
  120. Sun M,, 2017 Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma. Brain Behav. Immun 66, 359– 371. 28782716
  121. Thom M,, 2011 Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a postmortem study. Brain 134, 2969– 2981. 21903728 PMC3187539
  122. Thornton E,, 2006 Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 1094, 38– 46. 16697978
  123. Tian FF,, 2010 Potential roles of Cdk5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model. Clin. Lab 56, 127– 136. 20476644
  124. Utagawa A,, 2008 Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats. Exp. Neurol 211, 283– 291. 18355811 PMC2435258
  125. Van den Heuvel C,, 1999 Upregulation of amyloid precursor protein messenger RNA in response to traumatic brain injury: an ovine head impact model. Exp. Neurol 159, 441– 450. 10506515
  126. Villemagne VL,, 2013 Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12, 357– 367. 23477989
  127. Vossel KA,, 2013 Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70, 1158– 1166. 23835471 PMC4013391
  128. Vossel KA,, 2017 Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol 16, 311– 322. 28327340 PMC5973551
  129. Walsh DM,, 1999 Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 25945– 25952. 10464339
  130. Webster KM,, 2017 Inflammation in epileptogenesis after traumatic brain injury. J. Neuroinflammation 14, 10. 28086980 PMC5237206
  131. Wu J,, 2007 Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. Brain Res 1182, 82– 89. 17935702 PMC2153437
  132. Xu H,, 2017a The polarization states of microglia in TBI: a new paradigm for pharmacological intervention. Neural. Plast 2017, 5405104. 28255460 PMC5309408
  133. Xu X,, 2017b Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J. Neuroinflammation 14, 167. 28835272 PMC5569493
  134. Yan XX,, 2012a Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 36 x Tg-AD mice. Plos One 7 PMC3498246 23155407
  135. Yan XX,, 2012b BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice. Exp. Neurol 235, 228– 237. 22265658 PMC3514910
  136. Yang S,, 2014 Expression of amyloid-beta protein and amyloid-beta precursor protein after primary brain-stem injury in rats. Am J Forensic Med Pathol 35, 201– 205. 24949598
  137. Zeng X,, 2017 The expression of G protein-coupled receptor kinase 5 and its interaction with dendritic marker microtubule-associated protein-2 after status epilepticus. Epilepsy Res 138, 62– 70. 29080472
  138. Zheng P,, 2017 Animal Models of Acquired Epilepsy and Tauopathies Academic Press.

Cited by

Sorted by citations

Authors
Ali, I., Silva, J. C., Liu, S., Shultz, S. R., Kwan, P., Jones, N. C., & O'Brien, T. J.
Affiliations
The Royal Melbourne Hospital (AU)
Corresponding author
O'Brien, Terence J.
ORCID
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2019-03
Volume
123
Pages
100-109
ISSN
0969-9961 (ISSN-L)
DOI
10.1016/j.nbd.2018.08.006
PMC
PMC6348126
OpenAlex
W2887251520
Cited by
38
References
20
Citations by year
2026: 2 · 2025: 2 · 2024: 10 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 3
FWCI
0.57
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neurobiology of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute of Neurological Disorders and Stroke (U54NS100064)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Epidemiology › Traumatic Brain Injury Research
Keywords
post-traumatic epilepsy, neurodegeneration, traumatic brain injury, acquired epilepsy, therapeutic target, epilepsy pathophysiology
MeSH terms
Animals, Encephalitis, Epilepsy, Post-Traumatic, Humans, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Disease Progression, Neurodegenerative Diseases, Tauopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review